Please login to the form below

Not currently logged in
Email:
Password:

Purdue looks to Merck for new CEO

Mark Timney will lead pain specialist
Mark Timney, Purdue Pharma

Purdue Pharma has appointed Merck & Co veteran Mark Timney as CEO, replacing John Stewart who retires.

Timney spent 15 years at Merck, where he most recently served as president of global primary care.

His previous roles include president of Merck US, during which time he helped to launch the hepatitis C drug Victrelis (boceprevir) and led the acquisition of ophthalmology company Inspire Pharmaceuticals.

Prior to moving to the US, Timney served as Merck's country manager in Korea and then Japan following a period in Australia.

Before joining Merck, he spent eight years in sales and marketing at a number of pharmaceutical companies, including Zeneca in New Zealand, ICI Pharmaceuticals in Australia, and Roussel Labs in the United Kingdom

Dr Raymond Sackler, co-founder and board member of pain specialist Purdue, said they had found a “proven leader” in Timney.

"I am confident that his capabilities and experience, coupled with Purdue's culture of excellence, will grow our business and strengthen our healthcare industry leadership,” said Sackler.

30th January 2014

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...